Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 69

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 69
---
 well as Mr. Farrell’s discussions with Stockholder A. Members of management and the Board provided their perspectives on the merits and risks of engaging in further
discussions with Alcon or seeking a higher price from Alcon, including the risk of Alcon withdrawing its offer, as it had done in January 2025, and depriving STAAR’s stockholders of the opportunity to realize the premium offered in the
July 12 Offer. The Board also discussed the risks of proceeding with a potential transaction if Stockholder A was not supportive, in light of the requirement that the merger with Alcon would need to be approved by holders of a majority of
outstanding shares of STAAR common stock (and not only an approval by holders of a majority of the shares present at the meeting of STAAR’s stockholders). Following discussions, the Board directed STAAR’s management to again seek a
higher purchase price from Alcon.

On July 17, 2025, Mr. Farrell called Mr. Endicott, indicating that the Board believed
that a higher value was required before continuing with discussions. Also on July 17, 2025, representatives of Citi contacted representatives of Morgan Stanley to convey the same message. Alcon declined to offer a higher value.

On July 18, 2025, the Board held a meeting to discuss whether to continue further negotiations with Alcon and to discuss
Mr. Farrell’s interactions with Stockholder A. Members of management and the Board provided their perspectives on the merits and risks of engaging in further negotiations with Alcon. Among other things, the Board discussed the potential
of Alcon making a public offer for STAAR and the potential benefits to STAAR and its stockholders of a negotiated transaction. The Board also discussed the risks of proceeding with a potential transaction if Stockholder A did not support it, the
likelihood of obtaining stockholder approval of a transaction with Alcon, and the costs and risks associated with a transaction with Alcon that was not eventually consummated. Further, the Board discussed that STAAR’s other stockholders would
likely be supportive of a transaction with such a significant, certain premium and that it did not want to deprive all stockholders of an ability to consider such a transaction, and that stockholders would only have an opportunity to consider the
transaction if it were submitted to STAAR’s stockholders. In addition, the Board engaged in further discussions regarding the value represented by Alcon’s proposed offer, as well as potential risks and benefits of remaining